ClinicalTrials.Veeva

Menu

Exploration of the Relationship Between Inflammation and Integrity of the Blood-Brain Barrier in Suicidal Behaviour (IBIS)

University Hospital Center (CHU) logo

University Hospital Center (CHU)

Status

Unknown

Conditions

Depression

Treatments

Biological: Biological analysis

Study type

Interventional

Funder types

Other

Identifiers

NCT04137458
2019-A01277-50 (Other Identifier)
RECHMPL19_0227

Details and patient eligibility

About

Recent studies have revealed an association between history of suicide attempt and inflammatory markers in both the cerebrospinal fluid and the plasma. Post mortem studies have shown an increase in microglial activation in the brain tissue of suicide victims. However the relationship between peripheral and central inflammation in suicide is probably mediated by complex biological processes that are yet elucidated. An increase of blood S100B levels (biomarker of neurovascular damage; PMID 14530574) has been reported in adolescents with suicidal ideation vs. controls and independently of psychiatric disorder. The investigators hypothesize that peripheral inflammation may alter BBB which normally acts as a filter to ensure proper neuronal functioning in suicidal vs. non suicidal patients.

Full description

105 participants will be recruited :

  • 35 depressed patients having attempted suicide (maximum 3 attempts in life)
  • 35 depressed patients without history of suicide attempt (affective controls)
  • 35 healhy controls with no lifetime psychiatric history.

Only one visit is planned. A clinical assessment (2 hours) will be performed to characterise pschopathology and suicidal characteristics. Blood and salivary samples will be obtained in order to measure inflammatory markers.

Enrollment

105 estimated patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 18-55 years old
  • Able to understand nature, aims, and methodology of the study

Depending on the population :

  • Current depressive episode (according to DSM-5 criteria) with a recent suicide attempt (within the 8 days before inclusion) and no more than 3 attempts in life
  • Current depressive episode (according to DSM-5 criteria) without suicide attempt
  • No psychiatric history (according to DSM-5 criteria)

Exclusion criteria

  • Inflammatory diseases or intercurrent infections, or chronic diseases such as hepatitis C or B, HIV, Alzheimer's, cancer or autoimmune disease
  • Current antibiotic or anti-inflammatory treatments
  • Refusal to participate
  • Lifetime Schizoaffective disorder or schizophrenia
  • On protective measures (guardianship or trusteeship)
  • Deprived of liberty subject (administrative decision)
  • In exclusion period for another protocol
  • Not affiliated to a social security agency
  • Unable to understand and/or answer a questionnaire
  • Pregnant or lactating women

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

105 participants in 1 patient group

Participants
Experimental group
Description:
The investigator will withdraw biological samples and a biological and DNA bank will also be realized
Treatment:
Biological: Biological analysis

Trial contacts and locations

1

Loading...

Central trial contact

Philippe Courtet, MD PhD; Emilie Olie, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems